Nova Eye Medical Limited (ASX:EYE) disclosed on 19 November 2026 that 21,000 unquoted performance rights under the EYEAC security class have ceased following the lapse of conditional rights, as conditions attached to the securities have not been, or have become incapable of being, satisfied.
Key Points
- 21,000 EYEAC performance rights ceased on 19 November 2026 due to lapse of conditional rights
- The conditions attached to the securities have not been, or have become incapable of being, satisfied
- No consideration is being paid by the entity for the cessation
- Following the cessation, 28,000 EYEAC performance rights remain on issue
- Nova Eye Medical's total quoted ordinary fully paid shares on issue stand at 284,921,093
Performance Rights Cessation Details
According to the filing, the 21,000 securities that have ceased are classified under ASX security code EYEAC and are described as performance rights. These are unquoted equity securities. The cessation occurred on 19 November 2026, with the stated reason being the lapse of a conditional right to securities because the conditions have not been, or have become incapable of being, satisfied. The company disclosed that no consideration is being paid by the entity in connection with the cessation of these securities. No additional information was provided by the entity regarding the cessation.
Issued Capital Following the Cessation
Following the cessation of the 21,000 EYEAC performance rights, Nova Eye Medical's issued capital comprises 284,921,093 ordinary fully paid shares quoted on ASX under the code EYE. The remaining unquoted equity securities in the EYEAC performance rights class total 28,000. The filing noted that the figures provided are automatically generated and may not reflect the entity's current issued capital if other relevant forms are currently with ASX for processing at the time of the announcement.
Appendix 3H Notification Filed with ASX
Nova Eye Medical filed the notification as a new announcement under Appendix 3H, which governs the notification of cessation of securities. The filing was dated Thursday, 19 November 2026, and was submitted under the entity's ABN 15007702927 and ASX issuer code EYE. The company confirmed that the EYEAC performance rights class subject to this notification comprised unquoted equity securities. The filing did not disclose any further details regarding the conditions that were attached to the lapsed performance rights or any other matters relating to the cessation beyond those stated.




Please wait processing your request...